Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C

Marc C. Chamberlain, Sandra K. Johnston, Alixis Horn, Michael J. Glantz

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). Objective: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. Design: Clinical series of 14 patients with CSF positive lymphomatous meningitis. Setting: Tertiary-care university medical center. Results: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. Conclusions: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.

Original languageEnglish (US)
Pages (from-to)271-277
Number of pages7
JournalJournal of neuro-oncology
Volume91
Issue number3
DOIs
StatePublished - Jan 1 2009

Fingerprint

Cytarabine
Meningitis
Spine
Rituximab
Brain
Tertiary Healthcare
Non-Hodgkin's Lymphoma
Cause of Death
Appointments and Schedules
Radiotherapy
Central Nervous System
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Chamberlain, Marc C. ; Johnston, Sandra K. ; Horn, Alixis ; Glantz, Michael J. / Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. In: Journal of neuro-oncology. 2009 ; Vol. 91, No. 3. pp. 271-277.
@article{454c986f511c4a89bdc91a657cc92d7d,
title = "Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C",
abstract = "Background: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). Objective: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. Design: Clinical series of 14 patients with CSF positive lymphomatous meningitis. Setting: Tertiary-care university medical center. Results: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. Conclusions: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.",
author = "Chamberlain, {Marc C.} and Johnston, {Sandra K.} and Alixis Horn and Glantz, {Michael J.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s11060-008-9707-1",
language = "English (US)",
volume = "91",
pages = "271--277",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. / Chamberlain, Marc C.; Johnston, Sandra K.; Horn, Alixis; Glantz, Michael J.

In: Journal of neuro-oncology, Vol. 91, No. 3, 01.01.2009, p. 271-277.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C

AU - Chamberlain, Marc C.

AU - Johnston, Sandra K.

AU - Horn, Alixis

AU - Glantz, Michael J.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). Objective: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. Design: Clinical series of 14 patients with CSF positive lymphomatous meningitis. Setting: Tertiary-care university medical center. Results: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. Conclusions: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.

AB - Background: The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM). Objective: A clinical series to test the feasibility of combining intra-CSF liposomal ara-C and rituximab for the treatment of recurrent LM. Design: Clinical series of 14 patients with CSF positive lymphomatous meningitis. Setting: Tertiary-care university medical center. Results: Fourteen patients with recurrent, cytologically positive lymphomatous meningitis were treated. All 14 received liposomal ara-C and rituximab utilizing an Ommaya reservoir. Six patients also received involved-field radiotherapy (brain only two patients; brain and spine two patients; spine only two patients). Best response to treatment included 10 partial responses and four with progressive disease. Estimated median duration of response was 4.0 months (range 1-6 months). Survival ranged from 1.5 to 7 months with an estimated median of 5 months, four patients remain alive and continue to be followed. Cause of death was progressive neurological disease in 7, systemic disease in 1, and combined systemic and neurological disease in 2 patients. Conclusions: The combination of intra-CSF liposomal ara-C and rituximab administered in this schedule appears to have no additive toxicity and has modest palliative activity in patients with recurrent LM.

UR - http://www.scopus.com/inward/record.url?scp=58149470806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149470806&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9707-1

DO - 10.1007/s11060-008-9707-1

M3 - Article

C2 - 18820836

AN - SCOPUS:58149470806

VL - 91

SP - 271

EP - 277

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -